Precision Treatment in ACS-Role of Assessing Fibrinolysis.
acute coronary syndrome
endogenous fibrinolysis
precision medicine
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
01 Mar 2021
01 Mar 2021
Historique:
received:
29
01
2021
revised:
17
02
2021
accepted:
18
02
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
4
4
2021
Statut:
epublish
Résumé
Despite advancements in pharmacotherapy and interventional strategies, patients with acute coronary syndrome (ACS) remain at risk of recurrent thrombotic events. In addition to an enhanced tendency to thrombus formation, impairment in the ability to naturally dissolve or lyse a developing thrombus, namely impaired endogenous fibrinolysis, is responsible for a major part of this residual risk regardless of optimal antiplatelet medication. Global assessment of endogenous fibrinolysis, including a point-of-care assay, can identify patients with ACS at persistent high cardiovascular risk and might play an important role in allowing the personalisation of potent antithrombotic therapy to enhance fibrinolytic status, providing precision treatment of ACS to improve long-term outcome.
Identifiants
pubmed: 33804303
pii: jcm10050929
doi: 10.3390/jcm10050929
pmc: PMC7957496
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
J Am Coll Cardiol. 2010 Jun 15;55(24):2701-9
pubmed: 20538163
J Am Heart Assoc. 2018 Jan 26;7(3):
pubmed: 29374045
Am Heart J. 2000 Sep;140(3):379-84
pubmed: 10966534
Platelets. 2016 Nov;27(7):687-693
pubmed: 27094212
N Engl J Med. 2017 Sep 21;377(12):1119-1131
pubmed: 28845751
J Am Coll Cardiol. 2010 May 11;55(19):2107-15
pubmed: 20447533
JAMA. 2012 Nov 7;308(17):1785-94
pubmed: 23117779
N Engl J Med. 2017 Oct 5;377(14):1319-1330
pubmed: 28844192
N Engl J Med. 2002 Sep 26;347(13):969-74
pubmed: 12324552
Front Cardiovasc Med. 2019 Feb 28;6:16
pubmed: 30873416
Thromb Res. 2019 Jan;173:102-108
pubmed: 30500673
J Am Coll Cardiol. 2007 Apr 10;49(14):1505-16
pubmed: 17418288
Thromb Haemost. 2014 Jul 3;112(1):32-42
pubmed: 24671700
PLoS One. 2020 Jan 9;15(1):e0227054
pubmed: 31917789
Circulation. 2001 Apr 3;103(13):1718-20
pubmed: 11282900
Eur Heart J. 2018 Jan 7;39(2):119-177
pubmed: 28886621
Int J Cardiol. 2009 Aug 14;136(2):222-5
pubmed: 18625524
Curr Opin Cardiol. 2015 Jul;30(4):354-8
pubmed: 26049380
Int Heart J. 2009 Jan;50(1):33-45
pubmed: 19246845
Atherosclerosis. 2009 Oct;206(2):551-5
pubmed: 19394618
Anesthesiology. 2021 Mar 1;134(3):457-467
pubmed: 33417674
J Am Coll Cardiol. 2010 Sep 14;56(12):919-33
pubmed: 20828644
Eur Heart J. 2018 Apr 1;39(13):1078-1085
pubmed: 29390064
Thromb Res. 1982 Jan 1-15;25(1-2):51-70
pubmed: 6121390
N Engl J Med. 2012 Nov 29;367(22):2100-9
pubmed: 23121439
Int J Cardiol. 2007 Feb 7;115(2):203-7
pubmed: 16787670
Thromb Res. 2014 May;133(5):919-26
pubmed: 24613697
Lancet. 2017 Mar 11;389(10073):1025-1034
pubmed: 28290994
Eur Heart J. 2019 Jan 14;40(3):306-308
pubmed: 30496395
Circulation. 2004 Jun 8;109(22):2698-704
pubmed: 15184294
Int J Cardiol. 2014 Dec 20;177(3):847-53
pubmed: 25465831
J Thromb Thrombolysis. 2019 Apr;47(3):392-395
pubmed: 30739303
Thromb Haemost. 2020 Mar;120(3):412-422
pubmed: 31975352
Thromb Haemost. 2020 Apr;120(4):565-578
pubmed: 32074647
J Am Coll Cardiol. 2015 Apr 28;65(16):1683-1699
pubmed: 25908074
J Thromb Thrombolysis. 2020 Feb;49(2):192-198
pubmed: 31872349
Eur Heart J. 2021 Apr 7;42(14):1289-1367
pubmed: 32860058
N Engl J Med. 2012 Jan 5;366(1):9-19
pubmed: 22077192
Thromb Haemost. 2005 Aug;94(2):380-8
pubmed: 16113829
Europace. 2019 Sep 1;21(9):1297-1306
pubmed: 31505618
PLoS One. 2015 Aug 26;10(8):e0136463
pubmed: 26308340
J Thromb Haemost. 2005 Nov;3(11):2506-13
pubmed: 16241949
Neth Heart J. 2008 Jun;16(6):191-6
pubmed: 18665203
Eur Heart J. 2019 Jan 14;40(3):295-305
pubmed: 30380032
J Am Coll Cardiol. 2019 Sep 10;74(10):1366-1375
pubmed: 31488274
BMJ. 2006 Nov 25;333(7578):1091
pubmed: 17032691
Int J Cardiol. 2002 Apr;83(1):43-6
pubmed: 11959383